Mi-die Xu1,2,3, Lei Dong4,5,6, Peng Qi4,5,6, Wei-wei Weng4,5,6, Xiao-han Shen4,5,6, Shu-juan Ni4,5,6, Dan Huang4,5,6, Cong Tan4,5,6, Wei-qi Sheng4,5,6, Xiao-yan Zhou4,5,6, Xiang Du7,8,9,10. 1. Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. xumd27202003@sina.com. 2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. xumd27202003@sina.com. 3. Institute of Pathology, Fudan University, Shanghai, 200032, China. xumd27202003@sina.com. 4. Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. 5. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. 6. Institute of Pathology, Fudan University, Shanghai, 200032, China. 7. Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China. dx2008cn@163.com. 8. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. dx2008cn@163.com. 9. Institute of Pathology, Fudan University, Shanghai, 200032, China. dx2008cn@163.com. 10. Institutes of Biomedical Sciences, Fudan University, Shanghai, 200032, China. dx2008cn@163.com.
Abstract
BACKGROUND: Pituitary tumor-transforming gene-1 (PTTG1) is a transcription factor that can affect transcriptional activity, angiogenesis, and cell senescence. We examined PTTG1 mRNA and protein expression in gastric cancer (GC) cell lines and tissues to determine its value as a biomarker for GC diagnosis and therapy. METHODS: PTTG1 mRNA expression from 78 GC cases and paired adjacent normal mucosa (PCR cohort) as well as from five gastric cell lines was assessed using qRT-PCR. Nuclear and cytoplasmic RNA were extracted from two gastric cell lines to determine PTTG1 mRNA localization. PTTG1 protein expression from 98 GC cases, their paired adjacent normal mucosa, and 23 gastric intraepithelial neoplasia (GIN) cases was examined using immunohistochemistry (IHC cohort). The correlation between PTTG1 mRNA and protein expression and GC clinicopathological parameters was analyzed. RESULTS: PTTG1 mRNA expression in GC tissues and cell lines was significantly increased compared with adjacent normal gastric mucosa and normal gastric mucous cell lines (p < 0.05). PTTG1 expression was nuclear and cytoplasmic, with higher cytoplasmic expression. PTTG1 immunostaining significantly differed in GC (95.66 ± 20.65), GIN (84.00 ± 34.16), and normal adjacent mucosa (28 ± 22.25) (p < 0.001). Multivariate Cox regression analysis revealed that PTTG1 mRNA and protein expression are independent prognostic factors for GC patient survival. CONCLUSION: Our results suggest that PTTG1 is a promising target for GC diagnosis and therapy.
BACKGROUND:Pituitary tumor-transforming gene-1 (PTTG1) is a transcription factor that can affect transcriptional activity, angiogenesis, and cell senescence. We examined PTTG1 mRNA and protein expression in gastric cancer (GC) cell lines and tissues to determine its value as a biomarker for GC diagnosis and therapy. METHODS:PTTG1 mRNA expression from 78 GC cases and paired adjacent normal mucosa (PCR cohort) as well as from five gastric cell lines was assessed using qRT-PCR. Nuclear and cytoplasmic RNA were extracted from two gastric cell lines to determine PTTG1 mRNA localization. PTTG1 protein expression from 98 GC cases, their paired adjacent normal mucosa, and 23 gastric intraepithelial neoplasia (GIN) cases was examined using immunohistochemistry (IHC cohort). The correlation between PTTG1 mRNA and protein expression and GC clinicopathological parameters was analyzed. RESULTS:PTTG1 mRNA expression in GC tissues and cell lines was significantly increased compared with adjacent normal gastric mucosa and normal gastric mucous cell lines (p < 0.05). PTTG1 expression was nuclear and cytoplasmic, with higher cytoplasmic expression. PTTG1 immunostaining significantly differed in GC (95.66 ± 20.65), GIN (84.00 ± 34.16), and normal adjacent mucosa (28 ± 22.25) (p < 0.001). Multivariate Cox regression analysis revealed that PTTG1 mRNA and protein expression are independent prognostic factors for GC patient survival. CONCLUSION: Our results suggest that PTTG1 is a promising target for GC diagnosis and therapy.
Authors: Bill Wondergem; Zhongfa Zhang; Dachuan Huang; Choon Kiat Ong; Julie Koeman; David Van't Hof; David Petillo; Aikseng Ooi; John Anema; Brian Lane; Richard J Kahnoski; Kyle A Furge; Bin Tean Teh Journal: Cancer Res Date: 2012-07-17 Impact factor: 12.701
Authors: D S Kim; J A Franklyn; V E Smith; A L Stratford; H N Pemberton; A Warfield; J C Watkinson; T Ishmail; M J O Wakelam; C J McCabe Journal: Carcinogenesis Date: 2006-10-27 Impact factor: 4.944
Authors: Michael J Demeure; Kathryn E Coan; Clive S Grant; Richard A Komorowski; Elizabeth Stephan; Shripad Sinari; David Mount; Kimberly J Bussey Journal: Surgery Date: 2013-12 Impact factor: 3.982
Authors: N Gurvits; H Repo; E Löyttyniemi; M Nykänen; J Anttinen; T Kuopio; K Talvinen; P Kronqvist Journal: Cell Oncol (Dordr) Date: 2016-03-16 Impact factor: 6.730
Authors: Bin Zhu; Ming Gao; Lei Zhang; Juan Wang; Lei Wang; Ling Ling Qin; Xi Xiong Kang; Zhi Gang Zhao Journal: Metab Brain Dis Date: 2019-01-03 Impact factor: 3.584